Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
4(80.0%)
Early Phase 1
1(20.0%)
5Total
N/A(4)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05855694Not ApplicableNot Yet Recruiting

Photobiomodulation for Cancer-Related Cognitive Impairment

Role: lead

NCT04403802Not ApplicableCompleted

Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy

Role: lead

NCT03824132Not ApplicableCompleted

LOL: It's All Improv After Cancer!™

Role: lead

NCT05128838Early Phase 1Completed

RISE (Reinvent, Integrate, Strengthen, Expand) Self-Management Program for Cancer Survivors: A Feasibility Study

Role: lead

NCT04185610Not ApplicableTerminated

A Mind-Body Intervention for Chemotherapy-Induced Peripheral Neuropathy

Role: lead

All 5 trials loaded